TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04671667: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head a

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 188 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT04671667 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04671667 Rescue Dossier →